Kestra Medical posts Q2 FY25 results via press release

Kestra Medical Technologies, Ltd. furnished an update on its recent performance by announcing that it issued a press release with financial results for the fiscal quarter ended July 31, 2025.

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. furnished an update on its recent performance by announcing that it issued a press release with financial results for the fiscal quarter ended July 31, 2025. The company reported these quarterly results through a press release dated September 11, 2025, which is attached as an exhibit to this report.

The press release is provided for informational purposes and is designated as “furnished” rather than “filed,” meaning it is not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kestra Medical Technologies (KMTS) disclose in this 8-K?

Kestra Medical Technologies disclosed that it issued a press release announcing its financial results for the fiscal quarter ended July 31, 2025, and attached that press release as an exhibit.

Which period do the reported Kestra Medical Technologies (KMTS) results cover?

The financial results described in the press release cover the company’s fiscal quarter ended July 31, 2025.

When was the Kestra Medical Technologies (KMTS) earnings press release dated?

The press release announcing the quarterly financial results is dated September 11, 2025.

How is the Kestra Medical Technologies (KMTS) press release treated under securities laws?

The company states that the information in Item 2.02, including Exhibit 99.1, is furnished and not filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into other filings unless specifically referenced.

What exhibits are included with this Kestra Medical Technologies (KMTS) 8-K?

The 8-K includes Exhibit 99.1, the press release with quarterly results dated September 11, 2025, and Exhibit 104, the cover page interactive data file in Inline XBRL format.

Who signed this Kestra Medical Technologies (KMTS) current report?

The report is signed on behalf of the company by Brian Webster, who is its President and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 04:17 PM Learn about SEC filing dates

0001877184false00-000000000018771842025-09-112025-09-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2025

KESTRA MEDICAL TECHNOLOGIES, LTD.

(Exact name of Registrant as Specified in Its Charter)

Bermuda			001-42549	Not Applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
3933 Lake Washington Blvd NE Suite 200
Kirkland, Washington				98033
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (425) 279-8002

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, par value $1.00 per share		KMTS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On September 11, 2025, Kestra Medical Technologies, Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended July 31, 2025. A copy of the press release, dated September 11, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any registration statement or any other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Press Release of Kestra Medical Technologies, Ltd., dated September 11, 2025
104		Cover Page Interactive Data File, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Kestra Medical Technologies, Ltd.
Date: September 11, 2025		By:	/s/ Brian Webster
		Name:	Brian Webster
		Title:	President and Chief Executive Officer